Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Wednesday Mar 17, 2021
Wednesday Mar 17, 2021
touchCONGRESS for touchIMMUNOLOGY
Walter Maksymowych (University of Alberta, Alberta, Canada) talks to touchIMMUNOLOGY about the results of the C-axSpAnd Study (NCT02552212). This 52-week placebo-controlled study aimed to identify demographic or baseline characteristics of patients with nr-axSpA that could be predictive of achieving a clinical response to treatment with certolizumab pegol.
The abstract entitled ‘Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study’ was presented at ACR Convergence 2020, 5-9 November.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.